Quick Answer
Adaptive Biotechnologies Corp reported Diluted EPS of $0.39 per share (loss) for fiscal year 2025.
Adaptive Biotechnologies Corp Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.39 | +63.9% |
| 2024 | -$1.08 | +30.8% |
| 2023 | -$1.56 | -11.4% |
| 2022 | -$1.40 | +5.4% |
| 2021 | -$1.48 | -33.3% |
| 2020 | -$1.11 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.06 | +127.3% | +135.3% |
| June 30, 2025 | -$0.17 | +45.2% | +15.0% |
| March 31, 2025 | -$0.20 | +39.4% | +9.1% |
| September 30, 2024 | -$0.22 | +37.1% | +29.0% |
| June 30, 2024 | -$0.31 | +6.1% | +6.1% |
| March 31, 2024 | -$0.33 | +17.5% | +5.7% |
| September 30, 2023 | -$0.35 | -9.4% | -6.1% |
| June 30, 2023 | -$0.33 | +10.8% | +17.5% |
- Adaptive Biotechnologies Corp showed an increase of +63.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Adaptive Biotechnologies Corp’s diluted eps has grown by 64.9% (from $1.11 per share (loss) to $0.39 per share (loss)).
- The most recent figure is from Adaptive Biotechnologies Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: